The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group

Holly L. Geyer, Bjorn Andreasson, Heidi E. Kosiorek, Amylou C. Dueck, Robyn M. Scherber, Kari A. Martin, Kristina A. Butler, Claire N. Harrison, Deepti H. Radia, Francisco Cervantes, Jean Jacques Kiladjian, Andreas Reiter, Gunnar Birgegard, Francesco Passamonti, Zhenya Senyak, Alessandro M. Vannucchi, Chiara Paoli, Zhijian Xiao, Jan Samuelsson, Ruben Mesa

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

BACKGROUND Patients with myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and myelofibrosis, are faced with oppressive symptom profiles that compromise daily functioning and quality of life. Among these symptoms, sexuality-related symptoms have emerged as particularly prominent and largely unaddressed. In the current study, the authors evaluated how sexuality symptoms from MPN relate to other patient characteristics, disease features, treatments, and symptoms. METHODS A total of 1971 patients with MPN (827 with essential thrombocythemia, 682 with polycythemia vera, 456 with myelofibrosis, and 6 classified as other) were prospectively evaluated and patient responses to the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ C30) were collected, along with information regarding individual disease characteristics and laboratory data. Sexuality scores were compared with an age-matched, healthy control population. RESULTS Overall, patients with MPN were found to have greater sexual dysfunction compared with the healthy population (MPN-SAF score of 3.6 vs 2.0; P<.001), with 64% of patients with MPN describing some degree of sexual dysfunction and 43% experiencing severe symptoms. The presence of sexual symptoms correlated closely with all domains of patient functionality (physical, social, cognitive, emotional, and role functioning) and were associated with a reduced quality of life. Sexual problems also were found to be associated with other MPN symptoms, particularly depression and nocturnal and microvascular-related symptoms. Sexual dysfunction was more severe in patients aged >65 years and in those with cytopenias and transfusion requirements, and those receiving certain therapies such as immunomodulators or steroids. Conclusions The results of the current study identify the topic of sexuality as a prominent issue for the MPN population, and this area would appear to benefit from additional investigation and management.

Original languageEnglish (US)
Pages (from-to)1888-1896
Number of pages9
JournalCancer
Volume122
Issue number12
DOIs
StatePublished - Jun 15 2016
Externally publishedYes

Fingerprint

Sexuality
Quality of Life
Neoplasms
Essential Thrombocythemia
Polycythemia Vera
Primary Myelofibrosis
Population
Symptom Assessment
Immunologic Factors
Therapeutics
Steroids
Organizations
Research

Keywords

  • hematological neoplasms
  • myeloproliferative neoplasms
  • quality of life
  • sexuality
  • symptoms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life : An analysis by the MPN QOL International Study Group. / Geyer, Holly L.; Andreasson, Bjorn; Kosiorek, Heidi E.; Dueck, Amylou C.; Scherber, Robyn M.; Martin, Kari A.; Butler, Kristina A.; Harrison, Claire N.; Radia, Deepti H.; Cervantes, Francisco; Kiladjian, Jean Jacques; Reiter, Andreas; Birgegard, Gunnar; Passamonti, Francesco; Senyak, Zhenya; Vannucchi, Alessandro M.; Paoli, Chiara; Xiao, Zhijian; Samuelsson, Jan; Mesa, Ruben.

In: Cancer, Vol. 122, No. 12, 15.06.2016, p. 1888-1896.

Research output: Contribution to journalArticle

Geyer, HL, Andreasson, B, Kosiorek, HE, Dueck, AC, Scherber, RM, Martin, KA, Butler, KA, Harrison, CN, Radia, DH, Cervantes, F, Kiladjian, JJ, Reiter, A, Birgegard, G, Passamonti, F, Senyak, Z, Vannucchi, AM, Paoli, C, Xiao, Z, Samuelsson, J & Mesa, R 2016, 'The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group', Cancer, vol. 122, no. 12, pp. 1888-1896. https://doi.org/10.1002/cncr.30013
Geyer, Holly L. ; Andreasson, Bjorn ; Kosiorek, Heidi E. ; Dueck, Amylou C. ; Scherber, Robyn M. ; Martin, Kari A. ; Butler, Kristina A. ; Harrison, Claire N. ; Radia, Deepti H. ; Cervantes, Francisco ; Kiladjian, Jean Jacques ; Reiter, Andreas ; Birgegard, Gunnar ; Passamonti, Francesco ; Senyak, Zhenya ; Vannucchi, Alessandro M. ; Paoli, Chiara ; Xiao, Zhijian ; Samuelsson, Jan ; Mesa, Ruben. / The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life : An analysis by the MPN QOL International Study Group. In: Cancer. 2016 ; Vol. 122, No. 12. pp. 1888-1896.
@article{73b78171c4c04dfba6739dcc58da5e9e,
title = "The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group",
abstract = "BACKGROUND Patients with myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and myelofibrosis, are faced with oppressive symptom profiles that compromise daily functioning and quality of life. Among these symptoms, sexuality-related symptoms have emerged as particularly prominent and largely unaddressed. In the current study, the authors evaluated how sexuality symptoms from MPN relate to other patient characteristics, disease features, treatments, and symptoms. METHODS A total of 1971 patients with MPN (827 with essential thrombocythemia, 682 with polycythemia vera, 456 with myelofibrosis, and 6 classified as other) were prospectively evaluated and patient responses to the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ C30) were collected, along with information regarding individual disease characteristics and laboratory data. Sexuality scores were compared with an age-matched, healthy control population. RESULTS Overall, patients with MPN were found to have greater sexual dysfunction compared with the healthy population (MPN-SAF score of 3.6 vs 2.0; P<.001), with 64{\%} of patients with MPN describing some degree of sexual dysfunction and 43{\%} experiencing severe symptoms. The presence of sexual symptoms correlated closely with all domains of patient functionality (physical, social, cognitive, emotional, and role functioning) and were associated with a reduced quality of life. Sexual problems also were found to be associated with other MPN symptoms, particularly depression and nocturnal and microvascular-related symptoms. Sexual dysfunction was more severe in patients aged >65 years and in those with cytopenias and transfusion requirements, and those receiving certain therapies such as immunomodulators or steroids. Conclusions The results of the current study identify the topic of sexuality as a prominent issue for the MPN population, and this area would appear to benefit from additional investigation and management.",
keywords = "hematological neoplasms, myeloproliferative neoplasms, quality of life, sexuality, symptoms",
author = "Geyer, {Holly L.} and Bjorn Andreasson and Kosiorek, {Heidi E.} and Dueck, {Amylou C.} and Scherber, {Robyn M.} and Martin, {Kari A.} and Butler, {Kristina A.} and Harrison, {Claire N.} and Radia, {Deepti H.} and Francisco Cervantes and Kiladjian, {Jean Jacques} and Andreas Reiter and Gunnar Birgegard and Francesco Passamonti and Zhenya Senyak and Vannucchi, {Alessandro M.} and Chiara Paoli and Zhijian Xiao and Jan Samuelsson and Ruben Mesa",
year = "2016",
month = "6",
day = "15",
doi = "10.1002/cncr.30013",
language = "English (US)",
volume = "122",
pages = "1888--1896",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life

T2 - An analysis by the MPN QOL International Study Group

AU - Geyer, Holly L.

AU - Andreasson, Bjorn

AU - Kosiorek, Heidi E.

AU - Dueck, Amylou C.

AU - Scherber, Robyn M.

AU - Martin, Kari A.

AU - Butler, Kristina A.

AU - Harrison, Claire N.

AU - Radia, Deepti H.

AU - Cervantes, Francisco

AU - Kiladjian, Jean Jacques

AU - Reiter, Andreas

AU - Birgegard, Gunnar

AU - Passamonti, Francesco

AU - Senyak, Zhenya

AU - Vannucchi, Alessandro M.

AU - Paoli, Chiara

AU - Xiao, Zhijian

AU - Samuelsson, Jan

AU - Mesa, Ruben

PY - 2016/6/15

Y1 - 2016/6/15

N2 - BACKGROUND Patients with myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and myelofibrosis, are faced with oppressive symptom profiles that compromise daily functioning and quality of life. Among these symptoms, sexuality-related symptoms have emerged as particularly prominent and largely unaddressed. In the current study, the authors evaluated how sexuality symptoms from MPN relate to other patient characteristics, disease features, treatments, and symptoms. METHODS A total of 1971 patients with MPN (827 with essential thrombocythemia, 682 with polycythemia vera, 456 with myelofibrosis, and 6 classified as other) were prospectively evaluated and patient responses to the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ C30) were collected, along with information regarding individual disease characteristics and laboratory data. Sexuality scores were compared with an age-matched, healthy control population. RESULTS Overall, patients with MPN were found to have greater sexual dysfunction compared with the healthy population (MPN-SAF score of 3.6 vs 2.0; P<.001), with 64% of patients with MPN describing some degree of sexual dysfunction and 43% experiencing severe symptoms. The presence of sexual symptoms correlated closely with all domains of patient functionality (physical, social, cognitive, emotional, and role functioning) and were associated with a reduced quality of life. Sexual problems also were found to be associated with other MPN symptoms, particularly depression and nocturnal and microvascular-related symptoms. Sexual dysfunction was more severe in patients aged >65 years and in those with cytopenias and transfusion requirements, and those receiving certain therapies such as immunomodulators or steroids. Conclusions The results of the current study identify the topic of sexuality as a prominent issue for the MPN population, and this area would appear to benefit from additional investigation and management.

AB - BACKGROUND Patients with myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and myelofibrosis, are faced with oppressive symptom profiles that compromise daily functioning and quality of life. Among these symptoms, sexuality-related symptoms have emerged as particularly prominent and largely unaddressed. In the current study, the authors evaluated how sexuality symptoms from MPN relate to other patient characteristics, disease features, treatments, and symptoms. METHODS A total of 1971 patients with MPN (827 with essential thrombocythemia, 682 with polycythemia vera, 456 with myelofibrosis, and 6 classified as other) were prospectively evaluated and patient responses to the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ C30) were collected, along with information regarding individual disease characteristics and laboratory data. Sexuality scores were compared with an age-matched, healthy control population. RESULTS Overall, patients with MPN were found to have greater sexual dysfunction compared with the healthy population (MPN-SAF score of 3.6 vs 2.0; P<.001), with 64% of patients with MPN describing some degree of sexual dysfunction and 43% experiencing severe symptoms. The presence of sexual symptoms correlated closely with all domains of patient functionality (physical, social, cognitive, emotional, and role functioning) and were associated with a reduced quality of life. Sexual problems also were found to be associated with other MPN symptoms, particularly depression and nocturnal and microvascular-related symptoms. Sexual dysfunction was more severe in patients aged >65 years and in those with cytopenias and transfusion requirements, and those receiving certain therapies such as immunomodulators or steroids. Conclusions The results of the current study identify the topic of sexuality as a prominent issue for the MPN population, and this area would appear to benefit from additional investigation and management.

KW - hematological neoplasms

KW - myeloproliferative neoplasms

KW - quality of life

KW - sexuality

KW - symptoms

UR - http://www.scopus.com/inward/record.url?scp=84963735814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963735814&partnerID=8YFLogxK

U2 - 10.1002/cncr.30013

DO - 10.1002/cncr.30013

M3 - Article

C2 - 27070130

AN - SCOPUS:84963735814

VL - 122

SP - 1888

EP - 1896

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -